Cosentyx (secukinumab) is a biologic medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. As with any medication, it is important to monitor for potential side effects. According to the drug label, patients taking Cosentyx should be monitored for signs and symptoms of infection, including tuberculosis, before and during treatment [1].

In addition, the National Institutes of Health recommends monitoring patients for hypersensitivity reactions, such as anaphylaxis, during and after administration of Cosentyx [2]. Patients should also be monitored for changes in liver function tests and for signs of inflammatory bowel disease, as these have been reported in patients taking Cosentyx [1].

The dosing and monitoring of Cosentyx may vary depending on the condition being treated. For psoriasis, the recommended dose is 300 mg given as a subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks [3]. For psoriatic arthritis, the recommended dose is 150 mg or 300 mg given as a subcutaneous injection every 4 weeks [3].

Overall, patients taking Cosentyx should be closely monitored for potential side effects before and during treatment. The frequency of monitoring may depend on the patient's individual risk factors and the condition being treated. It is important for patients to communicate any new or worsening symptoms to their healthcare provider [1][2][3].

Sources:
[1] Cosentyx (secukinumab) drug label. Novartis Pharmaceuticals Corporation. Revised August 2020.
[2] National Institutes of Health. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Secukinumab. Last updated October 2019.
[3] Cosentyx website. Treatment and Dosing. Accessed November 2021.